Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects
Sponsor: Blue Earth Diagnostics
Listed as NCT02443571, this observational or N/A phase trial focuses on Prostatic Neoplasms and remains completed. Sponsored by Blue Earth Diagnostics, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Jan 2021 — Dec 2022 [monthly]
Completed
▶ Show 5 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Completed
-
Nov 2018 — Jan 2019 [monthly]
Completed
-
Jun 2018 — Nov 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Blue Earth Diagnostics
For direct contact, visit the study record on ClinicalTrials.gov .